SalaryGuide
SalariesCompaniesJobs
AboutPricingBlog
For Employers

Brand Marketing Jobs in Massachusetts

23 marketing jobs

Intellia Therapeutics, Inc. logo
5 weeks ago

Senior Director, Global Brand and US Marketing Lead (ATTR)

Intellia Therapeutics, Inc.

Cambridge, MA (On-site)Full time$275K/yr – $336K/yr
5 weeks ago

Brand Ambassador

HSSG Inc

Boston, MA (On-site)Part time
ThirdChannel logo
6 weeks ago

Brand Rep - Audits, Merchandising and Quality Control - $24/hr

ThirdChannel

Massachusetts, USA (On-site)Contract
Previous
12
Next

Related searches

  • Marketing Jobs in Massachusetts

Other roles in Massachusetts

  • General Marketing
  • Communications
  • Product Marketing
  • Social Media
  • Public Relations

Brand Marketing jobs in other places

  • California
  • New York
  • Illinois
  • Texas
  • New Jersey
  • Florida
  • Ohio
  • Virginia
  1. Jobs
  2. Brand Marketing

Brand Marketing jobs in Massachusetts

  1. Jobs
  2. Brand Marketing

Brand Marketing jobs in Massachusetts

23 jobs
Intellia Therapeutics, Inc. logo

Senior Director, Global Brand and US Marketing Lead (ATTR)

Intellia Therapeutics, Inc.

Cambridge, MA (On-site)

$275K/yr - $336K/yrIn-houseFull-timeSenior level10+ years exp.
5 weeks ago

Brand Ambassador

HSSG Inc

Boston, MA (On-site)

$58K/yr - $69K/yr (Est.)In-housePart-timeEntry level
5 weeks ago
ThirdChannel logo

Brand Rep - Audits, Merchandising and Quality Control - $24/hr

ThirdChannel

Massachusetts, USA (On-site)

In-houseContractEntry level
6 weeks ago
Previous12
Intellia Therapeutics, Inc. logo
Intellia Therapeutics, Inc.

Senior Director, Global Brand and US Marketing Lead (ATTR)

Cambridge, MA (On-site)

$275K/yr – $336K/yrSenior Level10+ years expFull time

Posted 5 weeks ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Description

Responsibilities

  • Global Brand Leadership: - Serve as a member of the Commercial Leadership Team, contributing broadly to Intellia’s commercialization success. - Represent the commercial function on the Program Leadership Team, the highest governance body accountable for all cross-functional aspects of the program, including clinical development activities. - Lead the development of the brand plan , global launch strategy, and global commercialization plan for the assigned brand in collaboration with key functions. - Deliver actionable recommendations to the leadership team through analysis, market research, and competitive intelligence. US Marketing Leadership: - Oversee the brand team, including colleagues executing all aspects of brand marketing to various stakeholders such as healthcare professionals (HCPs) and patients. - Lead the development of market development strategies in coordination with external agencies and cross-functional partners. - Lead the development of all branding efforts, including naming and creative campaigns. - Collaborate closely with the Commercial Operations team to generate insights that inform launch strategy and planning. - Collaborate across multiple functions, including Commercial Leadership, Sales, Marketing, Market Access, Medical, Legal, Regulatory, Compliance, and IT. - Oversee external vendors and consultants supporting the brand. - Manage the annual budget for the assigned brand. - Perform other duties as assigned. Supervisory Responsibilities: - Will manage 2–3 direct reports starting in 2027. - Recruits, interviews, hires, and trains new staff. - Oversee the daily workflow of the department. - Provide constructive and timely performance evaluations.

Requirements

  • Skills/Abilities: Demonstrated a bility to translate science into commercial strategies and compelling marketing narratives.
  • Proven a bility to foster productive relationships with external thought leaders and medical societies.
  • Excellent verbal, written, and interpersonal skills with the ability to influence senior management and establish effective working relationships with a diverse range of stakeholders.
  • Exceptional skills in proactivity, planning, prioritization, objective setting, meeting management, and plan execution.
  • Organized and logical, with a high degree of flexibility to change direction when needed.
  • A confident self-starter who can work independently and creatively, while also being a team player.
  • Must have demonstrated success in bringing novel and successful approaches that bring innovative products to patients.
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc.

3.4 Glassdoor

Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help.Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology’s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic.View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/ .

Founded in 2014
Cambridge, Massachusetts, USA
439 employees (9 in marketing)
www.intelliatx.com
56% recommend to a friend
69% CEO approval

Salaries

Posted range

$275K/yr – $336K/yr

Taken straight from the job posting.

See all Intellia Therapeutics, Inc. salaries

Marketing Team

Marketing Team Size
8 (2% of company)
Median Career Experience
18 years
Median Tenure
1.4 years
Marketing Roles Posted (Last 30 Days)
1

People

Marketing Leadership

David Waintraub
David Waintraub
Associate Director, Value and Access Marketing
At the company for 5 months

Funding

Total Funding
$1.5B
Last Raise
$300M
Post IPO Equity, 3 years ago

Funding History

  • Nov 2022
    Post IPO Equity • $300M
  • Jun 2021
    Post IPO Equity • $690M
  • Nov 2020
    Post IPO Equity • $201M

Traffic Signals

Monthly Visitors
48.1K
Traffic Source Mix
Search
53.1%
Direct
37.7%
Referral
7.2%
Social
0.7%
Paid
1.2%

Headcount Trend

Current headcount: ~439

Recent News

Intellia Therapeutics: A Worst-Case Risk Becomes A Tragic Reality (Downgrade)
Nov 19, 2025 • Seeking Alpha
Intellia Therapeutics Stock (NTLA) Opinions on Clinical Trial Suspension
Nov 18, 2025 • Quiver Quantitative
Intellia Therapeutics (NTLA): Assessing Valuation After FDA Clinical Hold on Lead Gene-Editing Program
Nov 11, 2025 • Yahoo Finance
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
Nov 10, 2025 • Yahoo Finance
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
Nov 10, 2025 • Intellia Therapeutics
Patient Treated in Trial for Intellia’s Transthyretin Amyloidosis Gene Editing Therapy Nex-Z Dies
Nov 9, 2025 • CGTLive®
Intellia Therapeutics Presents Positive Pooled Phase 1/2
Nov 8, 2025 • GlobeNewswire
Intellia Therapeutics Says a Patient Died in Gene Editing Trial
Nov 7, 2025 • Barron's
Intellia Tumbles After Patient Dies Following Crispr Treatment
Nov 7, 2025 • Bloomberg.com
Patient dies after receiving Intellia's CRISPR therapy
Nov 7, 2025 • Fierce Biotech
Patient Dies After Treatment with Intellia CRISPR Therapy in Phase III Trial - GEN
Nov 7, 2025 • GEN - Genetic Engineering and Biotechnology News
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
Nov 7, 2025 • Yahoo Finance
Intellia (NASDAQ: NTLA) completes HAELO Phase 3 enrollment; topline mid-2026
Nov 6, 2025 • Stock Titan
Intellia Therapeutics Inc earnings beat by $0.09, revenue fell short of estimates
Nov 6, 2025 • Investing.com
Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates
Nov 6, 2025 • Intellia Therapeutics
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates
Nov 6, 2025 • Yahoo Finance
Intellia Therapeutics: Irreversible Edit Vs. Reversible SOCs Now A Hard Sell (Rating Downgrade)
Oct 31, 2025 • Seeking Alpha
FDA places formal hold on two Intellia CRISPR trials
Oct 30, 2025 • BioPharma Dive
Intellia Puts Phase 3 Trials for Transthyretin Amyloidosis Gene Editing Therapy Nex-Z on Hold Following Grade 4 Liver AE
Oct 29, 2025 • CGTLive®
US FDA places clinical hold on Intellia's gene therapy trials; shares fall
Oct 29, 2025 • Reuters
Assessing Intellia Therapeutics After a 48% Price Drop and Clinical Updates in 2025
Oct 29, 2025 • Yahoo Finance
Intellia Therapeutics (NTLA) Is Down 45.2% After Pausing Key Nex-z Trials Over Safety Issue – Has The Bull Case Changed?
Oct 28, 2025 • Yahoo Finance
Intellia pauses two CRISPR drug studies after safety scare
Oct 27, 2025 • BioPharma Dive
Intellia Therapeutics Stock Drops as Safety Fears Emerge in Drug Trial
Oct 27, 2025 • Barron's
Intellia Pauses Gene Therapy Trials After Patient Hospitalized
Oct 27, 2025 • Bloomberg.com
Intellia Therapeutics: Insights on Recent Stock Performance
Oct 27, 2025 • StocksToTrade
For Intellia Therapeutics, CRISPR drug’s safety concern is an existential threat
Oct 27, 2025 • statnews.com
Intellia Therapeutics Temporarily Pauses Patient Dosing in MAGNITUDE Trials Following Reported Adverse Event
Oct 27, 2025 • Quiver Quantitative
Why Is Intellia Therapeutics Stock Sinking Monday? - Intellia Therapeutics (NASDAQ:NTLA)
Oct 27, 2025 • Benzinga
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
Oct 27, 2025 • Intellia Therapeutics
Intellia Therapeutics Plunges 44% After Update On Magnitude Clinical Trials
Oct 27, 2025 • Nasdaq
Intellia Therapeutics (NASDAQ: NTLA) pauses Phase 3 MAGNITUDE trials; more than 650 enrolled
Oct 27, 2025 • Stock Titan
Intellia Therapeutics stock hits 52-week high at 27.05 USD
Oct 20, 2025 • Investing.com
A Look at Intellia Therapeutics’s Valuation Following Breakthrough ATTR Data and HAELO Study Milestone
Oct 12, 2025 • Yahoo Finance
Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?
Oct 9, 2025 • Yahoo Finance
JMP Securities Upgrades Intellia Therapeutics (NTLA)
Oct 6, 2025 • Nasdaq
Intellia Therapeutics stock hits 52-week high at 21.49 USD
Oct 6, 2025 • Investing.com
65,200 RSUs: Intellia Grants Equity to Six New Hires, Vesting Over Three Years
Oct 3, 2025 • Stock Titan
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 3, 2025 • GlobeNewswire
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 3, 2025 • Yahoo Finance
How Investors May Respond To Intellia Therapeutics (NTLA) Reporting Three-Year Data on Gene-Editing Therapy
Sep 28, 2025 • Yahoo Finance
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Sep 25, 2025 • Intellia Therapeutics
90% Disease Protein Reduction Sustained for 3 Years: Intellia's Gene Editing Therapy Shows Promise in Rare Disease
Sep 25, 2025 • Stock Titan
Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
Sep 25, 2025 • Yahoo Finance
Intellia Therapeutics to Present Longer-Term Data from the
Sep 22, 2025 • GlobeNewswire
3 Years of Data: Intellia's Groundbreaking CRISPR Gene Therapy for Rare ATTR Disease Shows Long-term Results
Sep 22, 2025 • Stock Titan
Intellia Therapeutics to Present Long-Term Data on Investigational Nex-z for ATTR Amyloidosis at International Conference in Italy | NTLA Stock News
Sep 22, 2025 • Quiver Quantitative
Intellia Therapeutics Advances Lonvo-z Toward 2026 Launch - Keep This One On Your Watchlist
Sep 19, 2025 • RTTNews
Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength?
Sep 19, 2025 • Yahoo Finance
Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis (NTLA)
Sep 19, 2025 • Seeking Alpha
Intellia Therapeutics Completes Enrollment in the Global
Sep 18, 2025 • GlobeNewswire
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema
Sep 18, 2025 • Intellia Therapeutics
Intellia Therapeutics Completes Enrollment in Phase 3 HAELO Study for Lonvo-z, Aiming for 2027 U.S. Launch
Sep 18, 2025 • Quiver Quantitative
Intellia Therapeutics Shares Are Ripping Higher: Here's Why
Sep 18, 2025 • Benzinga
Gene Editing Breakthrough: Intellia's HAE Drug Trial Fully Enrolled, Could Transform Rare Disease Treatment
Sep 18, 2025 • Stock Titan
Intellia Therapeutics (NTLA) Surges 20% on Trial Enrollment Comp
Sep 18, 2025 • GuruFocus
Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Sep 18, 2025 • simplywall.st
Genome Editing Market to hit $37.22Bn by 2033, driven by CRISPR, rising genetic disorders & precision medicine demand.
Sep 1, 2025 • EIN Presswire
1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP)
Aug 29, 2025 • The Motley Fool
Cathie Wood's Raises Wager On Ethereum-Hoarding Bitmine: Ark Buys Stock Of Tom Lee-Backed Company, Dumps Shares Of Sports Betting Giant
Aug 27, 2025 • Benzinga.com
Cathie Wood Is Betting Big on Intellia Therapeutics. Should You Buy NTLA Stock Here?
Aug 21, 2025 • Barchart.com
9 Companies Hiring Now in Massachusetts
Aug 21, 2025 • BioSpace
Cathie Wood's ARK Investment buys 150.6K shares of Intellia Therapeutics today
Aug 21, 2025 • thefly.com
Cathie Wood's Ark Dumps $1.6 Million In Robinhood Stock Amid AI Launch Hype, Dumps Shopify Stock As Well
Aug 21, 2025 • Benzinga.com
Cathie Wood's 'Apocalypse Squad' Play? Ark Scoops Up $14.2 Million Worth Of Robinhood Stock
Aug 18, 2025 • Benzinga.com
Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade) (NASDAQ:NTLA)
Aug 15, 2025 • Seeking Alpha
Gene Editing Market Size, Share, Growth, and Forecasts 2021-2024 & 2025-2033 | Focus on CRISPR-Cas9 (CRISPR), TALEN, ZFN (Zinc Finger), and Antisense - ResearchAndMarkets.com
Aug 15, 2025 • Business Wire
Intellia Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year
Aug 14, 2025 • Investing.com
Analysts Are Upgrading Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest Results
Aug 11, 2025 • Yahoo Finance
Prime Editing and CRISPR Market Worth USD 23.493 Billion by 2030 at a CAGR of 24.3%
Aug 11, 2025 • EIN Presswire
Walt Disney To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday
Aug 11, 2025 • Benzinga.com
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2025 Earnings Call Transcript
Aug 9, 2025 • Insider Monkey
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Market Research 2025 | Key Players Include Intellia Therapeutics, Renowned for NTLA-2001 in Phase III Development, Leveraging CRISPR/Cas9
Aug 8, 2025 • Research and Markets
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress
Aug 8, 2025 • BioSpace
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates
Aug 7, 2025 • Yahoo Finance
Earnings call transcript: Intellia Therapeutics beats Q2 2025 forecasts
Aug 7, 2025 • Investing.com
Gene Editing Research Forecasts Report 2025 | Market to Reach $22 Billion by 2033 - Key Dynamics, Opportunities, Future Road Map, Competitive Landscape and Major Trends
Aug 7, 2025 • Research and Markets
Intellia Therapeutics sees cash runway into 1H27
Aug 7, 2025 • thefly.com
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress
Aug 7, 2025 • Intellia Therapeutics, Inc.
Transcript : Intellia Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025
Aug 7, 2025 • MarketScreener
Intellia Therapeutics price target lowered by $4 at RBC Capital, here's why
Aug 7, 2025 • thefly.com
Intellia Therapeutics reports Q2 EPS (98c), consensus ($1.01)
Aug 7, 2025 • thefly.com
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aug 1, 2025 • GlobeNewswire
Intellia Therapeutics announces employee inducement grants
Aug 1, 2025 • thefly.com
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
Jul 31, 2025 • Intellia Therapeutics, Inc.
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
Jul 7, 2025 • Yahoo Finance
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Jul 7, 2025 • GlobeNewswire
Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?
Jun 21, 2025 • Yahoo Finance
Intellia Reports Positive Three-Year Follow-up Data from Phase 1 CRISPR Trial in Hereditary Angioedema
Jun 18, 2025 • CRISPR Medicine News
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential
Jun 17, 2025 • Yahoo Finance
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
Jun 15, 2025 • Intellia Therapeutics
Intellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients
Jun 15, 2025 • Nasdaq
CRISPR Technology Market Set to Reach USD 14.75 Billion by 2032, Driven by Expanding Applications in Gene Editing, Drug Discovery, and Agriculture – SNS Insider
Jun 11, 2025 • SNS Insider pvt ltd
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - June 5, 2025
Jun 6, 2025 • BioSpace
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Jun 5, 2025 • Intellia Therapeutics, Inc.
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%
Jun 4, 2025 • Yahoo Finance
Gene Editing Tools Market Set to Surge Past USD 690.41 Million with 18.50% CAGR by 2032
Jun 4, 2025 • EIN Presswire
CRISPR Market is expected to generate a revenue of USD 12.78 Billion by 2032, Globally, at 15.85% CAGR: Verified Market Research®
Jun 2, 2025 • PR Newswire
CRISPR Market is expected to generate a revenue of USD 12.78 Billion by 2032, Globally, at 15.85% CAGR: Verified Market Research®
Jun 2, 2025 • PR Newswire UK
SA analyst downgrades: PLTR, PSTG, NTLA, ARWR
May 30, 2025 • Seeking Alpha

Links

www.intelliatx.comLinkedInX (Twitter)Crunchbase

This role is listed on SalaryGuide for informational purposes. SalaryGuide is not the employer, recruitment agency, or hiring representative for this position. Hiring decisions and the application process are managed by the employer. SalaryGuide will never ask candidates to pay to apply for a job or request bank details or identification documents as part of an application.